Page 172 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $22.14
52wk Low $0.12 Tonix Pharmaceuticals Hold TNXP $0.13
26 Main Street
Chatham, NJ 07928

(USD - in millions) www.tonixpharma.com
Market Cap 23.4
Enterprise (4.8)
Basic Shares Out. 178.58 COMPANY OVERVIEW
Float 178.58
Institutional Holdings 0.76% Detailed Analysis:Channelchek.com
Short Interest 7.67
Avg. 90-Day Volume 31.88 Tonix is a fully-integrated biopharmaceutical company focused on
transforming therapies for pain management and vaccines for public
health challenges. Tonix’s development portfolio is focused on central
nervous system (CNS) disorders. Tonix’s priority is to advance TNX-
EPS Data 102 SL, a product candidate for the management of fibromyalgia, for
which an NDA was submitted based on two statistically significant
2022 2023 2024 Phase 3 studies for the management of fibromyalgia. The FDA has
CQ1 (320.00) (104.00) (5.76) granted Fast Track designation to TNX-102 SL for the management of
CQ2 (244.00) (85.76) (19.28) fibromyalgia. We expect an FDA decision on the acceptance of the
NDA for review and an assigned PDUFA date in December and if
CQ3 (138.00) (58.56) (0.23) accepted, a decision on NDA approval in 2025.
CQ4 (112.00) 17.60 (3.95)
CY (654.00) (219.20) (18.72) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.19
ROE (ttm) -138.69
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
26 Main StreetChatham NJ 07928

Key Executives
CEO: Lederman, Seth
CFO: Saenger, Bradley
COO: Morris, Jessica
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures